Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program
Related Experiment Videos
K C Kugler1, G A Denys, M L Wilson
1Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA, USA.
Abstract:
The emergence and sustained prevalence of Gram-positive organisms resistant to antimicrobials has been of interest for over a decade. Quinupristin/dalfopristin (formerly RP 59500 or Synercid) is a new injectable streptogramin combination that has been reported to have activity against Gram-positive organisms, even those with documented MLS(B) resistance. However, the two case reports presented here illustrate three well-documented Streptococcus spp. strains (S. mitis, S. pneumoniae) to be resistant to quinupristin/dalfopristin (MICs at 3, 8, and 12 microg/ml) following referral as routine isolates in the SENTRY Antimicrobial Surveillance Program. The S. pneumoniae pleural fluid isolate was cross-resistant to erythromycin. Both bacteremic S. mitis strains were resistant to macrolides (erythromycin, azithromycin, clarithromycin), lincosamides (clindamycin), and fluoroquinolones. Patient histories indicated no prior use of MLS class antimicrobials for the S. mitis case, but the patient having the S. pneumoniae isolate did receive prior treatment of erythromycin and clindamycin. All isolates had modestly increased penicillin MICs of 0.12 microg/ml. The mode of resistance to quinupristin/dalfopristin was not evident (sat A-negative by PCR); and these cases illustrate the existence of streptogramin-resistant isolates before the introduction of this antimicrobial class into human clinical practice.
Insights
Antimicrobial resistance is a growing concern. Three Streptococcus strains showed resistance to quinupristin/dalfopristin, even before its clinical introduction, highlighting emerging resistance challenges.
Area of Science:
- Microbiology
- Antimicrobial Resistance
Background:
- Gram-positive organisms exhibit increasing antimicrobial resistance.
- Quinupristin/dalfopristin is a streptogramin antibiotic with reported activity against resistant Gram-positive bacteria.
Observation:
- Three Streptococcus spp. isolates (S. mitis, S. pneumoniae) demonstrated resistance to quinupristin/dalfopristin.
- Resistance was observed in routine isolates within the SENTRY Antimicrobial Surveillance Program.
- Cross-resistance to other antibiotics like erythromycin, macrolides, lincosamides, and fluoroquinolones was noted in some strains.
Findings:
- The Streptococcus strains exhibited minimum inhibitory concentrations (MICs) of 3, 8, and 12 microg/ml for quinupristin/dalfopristin.
- One S. pneumoniae isolate was cross-resistant to erythromycin.
- Two S. mitis isolates showed resistance to macrolides, lincosamides, and fluoroquinolones.
- All isolates had elevated penicillin MICs (0.12 microg/ml).
- The mechanism of resistance to quinupristin/dalfopristin was not identified (sat A-negative).
Implications:
- These findings indicate the presence of streptogramin-resistant Streptococcus isolates prior to the widespread clinical use of quinupristin/dalfopristin.
- This underscores the need for ongoing surveillance of antimicrobial resistance patterns.
- Emergence of resistance necessitates careful monitoring and potential development of alternative therapeutic strategies.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Streptococcal Pharyngitis
Gene Regulation in Microbial Communities: Quorum Sensing
Staphylococcal Skin Infections
Inhibitors of Bacterial DNA Synthesis